GenEng News  Mar 20  Comment 
Novartis will partner with researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for second-generation cancer immunotherapies, the pharma...
FiercePharma  Mar 20  Comment 
Chinese premier Li Keqiang said China will nix import tariffs on foreign anticancer drugs, a plan that could benefit foreign cancer drugmakers like Roche, Novartis and AstraZeneca, while prompting local pharmas to amp up their games.
The Economic Times  Mar 20  Comment 
Novartis India, with domestic sales of nearly Rs 1,200 crore, has been battling it out in the Indian market with several drug companies in the anti-diabetic space.
The Hindu Business Line  Mar 17  Comment 
Novartis India today said its Vice-Chairman and Managing Director Jawed Zia has decided to step down from the post. “Jawed Zia, Vice-Chairman and Managing Director, Novartis India Ltd, has inform
FiercePharma  Mar 13  Comment 
ORLANDO, Fla.—When Novartis released results from a 10,000-patient trial examining canakinumab—already approved as rare disease med Ilaris—last year, analysts initially questioned its future as a cardio drug. Now, the drugmaker is touting...
FiercePharma  Mar 12  Comment 
Novartis just rejigged its executive committee for three obvious reasons: Its operations chief is leaving, it’s aiming for big things in digital and it needs to tighten focus on ethics and compliance after a series of scandals around the globe.
The Hindu Business Line  Mar 12  Comment 
Novartis’ new Chief Executive Vas Narasimhan is remaking the Swiss drugmaker’s leadership as Operations President Andre Wyss exits and three others, including a digital specialist and the company
FierceBiotech  Mar 7  Comment 
Big Pharma Novartis is teaming up with virtual clinical trial company Science 37 to boost the Swiss major’s ability to run “site-less” studies.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki